Thyroid Disorders in Saudi Arabia: Causes, Symptoms, Treatment & Prevention

Prevalence & Risk Factors Specific to Saudi/Gulf

Local studies indicate substantial rates of thyroid test abnormalities, though reported prevalence varies by sample. A cross-sectional registry-based study in the ASIR region reported thyroid dysfunction in 49.8% of those tested—characterized by a high proportion of subclinical hypothyroidism—highlighting the frequency of laboratory-detected thyroid abnormalities in clinical practice. These figures should be interpreted in context: many represent the tested population rather than the general population. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8395449/?utm_source=openai))

Among pregnant Saudi women, a study of 810 participants reported gestational thyroid disorders in 32.7% (20.2% subclinical hypothyroidism; 5.8% overt hypothyroidism; 4.7% isolated hypothyroxinemia; 2% hyperthyroidism). The same study linked lower urinary iodine concentrations and not using iodized salt or supplements to higher risk, and found dietary patterns (lower dairy/seafood/egg intake) were associated with increased gestational thyroid disorders. These findings underscore the role of iodine adequacy in pregnancy-related thyroid health. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32710351/))

National cancer registry and hospital reports indicate rising detection of thyroid cancer over recent decades in Saudi Arabia—partly attributable to increased diagnostic imaging and surveillance—requiring nuanced interpretation for public health planning. High-risk groups include females, those with family history, prior neck irradiation, and pregnant women. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9689402/?utm_source=openai))

Common Thyroid Disorders Explained

Clinical thyroid disorders typically fall into four groups:

• Hypothyroidism: May be overt or subclinical. In iodine-sufficient settings autoimmune (Hashimoto's) is a leading cause; symptoms include fatigue, weight gain, cold intolerance, constipation and menstrual disturbances. Diagnosis is biochemical (elevated TSH, low free T4 in overt disease). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6619426/?utm_source=openai))
• Hyperthyroidism: Common causes are Graves' disease and toxic nodular goitre. Symptoms include weight loss, palpitations, tremor, heat intolerance and insomnia. Treatments include antithyroid drugs, radioactive iodine and surgery depending on cause and severity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27038492/?utm_source=openai))
• Thyroiditis: Encompasses painful (subacute/de Quervain) and painless autoimmune variants; clinical course may include transient thyrotoxicosis followed by hypothyroidism and eventual recovery in some cases.
• Nodules and thyroid cancer: Thyroid nodules are common; most are benign but ultrasound assessment and fine-needle aspiration (FNA) are used to stratify cancer risk. Saudi registry data show changes in incidence patterns over time, necessitating local diagnostic algorithms. ([shc.gov.sa](https://shc.gov.sa/Arabic/NewNCC/Activities/AnnualReports/Cancer%20Incidence%20Report%202023.pdf?utm_source=openai))

Symptoms and Diagnostic Tests: When to Test

Because thyroid disease symptoms are often nonspecific, targeted testing is recommended for people with suggestive clinical features or risk factors (pregnancy, family history, neck irradiation, autoimmune disease). Routine population-wide screening in asymptomatic adults is not universally recommended; instead, a case-finding approach is supported by systematic reviews. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6859607/?utm_source=openai))

Initial laboratory testing should begin with serum TSH. If TSH is abnormal, free T4 measurement helps classify overt versus subclinical disease. Thyroid peroxidase antibodies (Anti-TPO) and thyroglobulin antibodies (Anti-Tg) assist in diagnosing autoimmune thyroiditis. Neck ultrasound is indicated for palpable nodules or suspicious clinical assessment; FNA cytology is the gold standard to evaluate nodules for malignancy. In hyperthyroid patients, radioactive iodine uptake may help distinguish causes when clinically necessary. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6619426/?utm_source=openai))

Treatment Options and Local Care Pathways in Saudi Arabia

Treatment modalities available across Saudi healthcare settings mirror international practice: levothyroxine replacement for hypothyroidism; antithyroid medications (e.g., methimazole) for Graves' disease; radioactive iodine therapy in nuclear medicine centers; and thyroidectomy for selected nodular disease or refractory hyperthyroidism. Choice of therapy depends on etiology, patient age, pregnancy plans and comorbidities. Follow-up and dose titration of levothyroxine are essential, and many Saudi tertiary centers offer multidisciplinary care (endocrinology, nuclear medicine, surgery). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27038492/?utm_source=openai))

After definitive treatments (surgery or radioiodine) patients often require lifelong endocrine follow-up for hormone replacement or surveillance. Pregnant women require special attention: levothyroxine requirements often increase during pregnancy and should be monitored and adjusted frequently. National registries and tertiary centers provide outcome data that inform local clinical pathways and resource allocation. ([shc.gov.sa](https://shc.gov.sa/Arabic/NewNCC/Activities/AnnualReports/Cancer%20Incidence%20Report%202023.pdf?utm_source=openai))

Prevention, Long-Term Management and Local Resources

Primary prevention at the population level focuses on adequate iodine nutrition through universal salt iodization and region-specific monitoring, as WHO recommends. National surveys in Saudi Arabia indicate overall national progress but also regional variability with pockets of iodine insufficiency, particularly in some highland areas—reinforcing the need for ongoing surveillance and targeted interventions. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27553396/?utm_source=openai))

Long-term management of thyroid disease includes regular monitoring of TSH and free T4 to guide medication adjustments, bone density assessment for long-term replacement patients at risk of osteoporosis, and cardiovascular risk assessment given associations between thyroid dysfunction and heart disease. For women of reproductive age, preconception counseling and pregnancy-specific monitoring reduce adverse obstetric and neonatal outcomes. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30196268/?utm_source=openai))

Lifestyle measures complement medical therapy: balanced dietary iodine intake (iodized salt, dairy, seafood and eggs), weight management, smoking cessation, and attention to drug–nutrient interactions (levothyroxine absorption can be affected by calcium, iron and some foods). Programs like Feel Great—which emphasize adequate dietary fiber and include supportive botanical beverages such as Unimate—can aid symptom management (e.g., constipation in hypothyroidism, energy levels in fatigue) as adjuncts to, not replacements for, medical care. Evidence for direct effects of yerba mate on thyroid hormones is limited, so such products should be used cautiously and discussed with clinicians.

"Monitoring population iodine status and ensuring targeted screening of high-risk groups are essential public health measures to reduce the burden of thyroid disease." — WHO guidance on iodine indicators.

Selected local statistics (table)

Summary: Thyroid disorders represent a significant endocrine and public-health issue in Saudi Arabia with notable regional variability and specific concerns in pregnancy and detection of thyroid nodules. Practical steps include targeted case-finding, robust iodine monitoring programs, multidisciplinary local care pathways, and patient-centered lifestyle support. Integrating structured lifestyle programs (including fiber emphasis and supportive products like Unimate within the Feel Great system) can improve symptom management and quality of life when used alongside evidence-based medical treatment. For clinical decision-making, clinicians and health planners should rely on national registry data, local surveys and international guidelines (WHO, ATA, Lancet reviews) referenced above.